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Abstract 
 
Lactic acid bacteria (LAB) are present in the intestine and the beneficial role played 
by these microorganisms in humans has been extensively reported. They are 
frequently used as probiotics to improve some biological functions in the host and 
various studies have found that probiotic bacteria provide a beneficial effect on gut 
mucosal function, suggesting their potential effect in the treatment of inflammatory 
bowel diseases. LAB have been shown to activate both systemic and secretory 
immune responses via many complex interactions among the different components 
of the intestinal ecosystem, such as microflora, epithelial cells and other immune 
cells (Perdigon et al., 2001). There are numerous strains of lactic acid bacteria, but 
this review will focus particularly on the effects of Lactobacillus casei and more 
specifically Lactobacillus casei Shirota, the probiotic used in the commercially 
available Yakult probiotic drink.  
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Gut Mucosal Immunity 
To understand the effect lactic acid bacteria such as Lactobacillus casei Shirota 
have on gut mucosal function, it is first important to understand the structure of 
intestinal mucosa and the role of commensal bacteria.  
  
The majority of epithelial surfaces of the body, such as the skin and gut mucosa, are 
colonized by a vast number of microorganisms; the so-called normal ‘microflora’ or 
commensal bacteria (Eckburg et al., 2005). Starting from the first hours after the 
birth, interaction with micro-organisms begins (Tlaskalova-Hogenova et al., 2004) 
and the human microbiota is made up of trillions of bacterial cells, the majority of 
which are found in the gut, particularly in the large intestine (Eckburg et al., 2005). 
The main route of entry for microbes is the skin and mucosal surfaces of the 
gastrointestinal, respiratory and urogenital tracts where colonisation of epithelial 
surfaces takes place and a symbiotic co-existence is formed that is beneficial for the 
host (Tlaskalova-Hogenova et al., 2011). Most exogenous pathogens also enter their 
host via muscosal surfaces (Hill and Artis, 2010) and therefore almost 80% of the 
immunologically active cells of the body belong to the mucosal-associated immune 
system in the gut. These cells are present in tissues of the gastrointestinal tract, 
where the prevalence of immunogenic agents, such as food and components of the 
commensal bacteria, is the highest (Hill and Artis, 2010).   
 
The barrier function of mucosal surfaces in the gut involves a number of complex 
mechanisms working on several levels. The commensal bacteria themselves form an 
important part of these natural mechanisms that provide protection against 
pathogenic microorganisms (Chung and Kasper, 2010; Turner, 2009). They play an 
important role in pathogen resistance, by direct interaction with pathogenic bacteria 
and by priming the host immune system, resulting in mucosal tolerance (Turner, 
2009; Foey, 2012). When there is an optimal composition of commensal bacteria 
several events take place: they prevent attachment and multiplication of pathogenic 
or virulent microorganisms on these surfaces, and inhibit the invasion of these 
microorganisms into epithelial cells and subsequently the host’s circulatory system 
by outcompeting possible pathogens for nutrients and attachment sites (Chung and 
Kasper, 2010). The first major barrier between the gut contents and epithelial cells is 
provided by a class of highly glycosylated macromolecules called mucins, which 
protect gut epithelial cells from direct contact with commensal bacteria and their 
components (Linden et al., 2008). Another constituent of barrier defences is the 
secretion of mucus, which traps pathogenic organisms; it is secreted by goblet cells 
that are interspersed with epithelial cells in the lining of the gut (Foey, 2012). The 
epithelial layer of the gut mucosa is also reinforced by junctions, such as tight 
junctions, adherens junctions and desmosomes, in the paracellular spaces between 
epithelial cells (Chung and Kasper, 2010). Tight junctions have been shown to act as 
strictly regulated points of entry that open and close in response to various signals 
such as cytokines and bacterial components originating in the lumen, lamina propria 
and epithelium of the gut (Tlaskalova-Hogenova et al., 2011).  
 
Components of innate immunity such as complement, lysozymes, lactoferrin and 
mannan-binding protein also have a role in gut mucosal immunity (Medzhitov and 
Janeway, 2000). Epithelial cells facilitate the repulsion of pathogenic organisms by 
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secreting anti-microbial peptides such as defensins (Foey, 2012). Multiple types of 
defensins are also produced by Paneth cells, specialized cells present in the crypts 
of the gut mucosa. In general, innate immune mechanisms to microbes are initiated 
by phagocytic cells such as macrophages, neutrophils and dendritic cells, via pattern 
recognition receptors (PRRs), which produce cytokines essential for inflammatory 
reactions and factors critical for the subsequent initiation of adaptive immunity 
(Medzhitov and Janeway, 2000). PRRs, such as Toll-like receptors, C-type lectin 
receptors, RIG-I-like receptors and nucleotide-binding domain (NODs) sense 
pathogen-associated molecular patterns (PAMPs) and transmit activation signals to 
their target cells (Tlaskalova-Hogenova et al., 2011).  Phagocytic cells such as 
macrophages and dendritic cells are generally located close to the gut epithelium, so 
they can quickly recognise invading pathogens and initiate an inflammatory response 
as well as exert primary defences through phagocytosis (Mannon, 2005). Intestinal 
adaptive immunity is mediated by Peyer's patches in the small intestine which 
contain immune cells such as T and B lymphocytes (Mowatt and Viney, 1997). The 
overlying layer of follicle-associated epithelium of the Peyer's patches contains 
specialized epithelial cells which have microfolds on their luminal surface, instead of 
microvilli like on epithelial cells of the intestine, and are known as microfold cells or 
M cells (Medzhitov and Janeway, 2000). They form a membrane overlying the 
lymphoid tissue within the Peyer's patch and are adapted to interact directly with 
molecules and particles within the lumen of the gut (Mowatt and Viney, 1997). 
Gut Pathologies 
Most of the commensal bacteria are symbiotic; however, after translocation through 
the mucosa or under specific conditions, for example in the case of 
immunodeficiency, commensal bacteria can cause disease (Tlaskalova-Hogenova et 
al., 2004).  An example of such a pathology is Inflammatory Bowel Disease (IBD) 
(Tlaskalova-Hogenova et al., 2011), which covers several chronic inflammatory 
disorders. The two principal forms of these disorders are Crohn’s disease and 
Ulcerative Colitis which affect approximately 0.2% of the population (Tlaskalova-
Hogenova et al., 2011). Even though there has been much research in this field, the 
aetiology and pathogenesis of these diseases remain unclear. However, the 
combination of immune, environmental and genetic factors is thought to result in the 
induction of inflammation and the subsequent development of mucosal lesions seen 
in both diseases (Xavier and Podolsky, 2007).  Disruption of T lymphocyte regulatory 
functions and abnormal mucosal immune responses to commensal bacteria has 
been shown to play an important role in the pathogenesis of chronic intestinal 
inflammation (Bengmark, 2007). This suggests that the gut mucosa is a sensitive 
indicator of immune dysfunction. This abnormal T-cell response against commensal 
bacteria in IBD suggests that commensal bacteria may initiate the intestinal 
inflammation seen in this disease (Bengmark, 2007).  
 
Increased interest in the effects of the intestinal microbiota on human health has 
resulted in attempts to optimise the composition of the microbiota using probiotics 
(O’Flaherty et al., 2010). The most commonly used microorganisms in probiotic 
products are lactic acid bacteria (LAB) and various studies have found these 
probiotic bacteria provide a beneficial effect on gut mucosal function suggesting their 
potential effect in the treatment or alleviation of inflammatory bowel diseases 
(O’Flaherty et al., 2010).  
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Lactobacillus casei and gut pathologies 
The effects of LAB such as Lactobacillus casei on gut pathologies such as IBD have 
been established in numerous studies.  It has been demonstrated in an IL-10 
knockout mice model of colitis that probiotic therapy with L. casei is effective in 
reducing inflammation (Madsen et al., 1999; McCarthy et al., 2003). Madsen et al. 
(1999) demonstrated that by restoring Lactobacillus species such as L. casei to 
normal levels in the gut, this reduced levels of pathogenic bacteria and thus 
prevented the development of colitis. This was substantiated by McCarthy et al. in 
2003 who found that the production of pro-inflammatory cytokines from Peyer’s 
patches was reduced in the probiotic fed mice, suggesting that L. casei had an effect 
on the mucosal immune system.  L. casei has also been shown to reduce the 
inflammatory response in Crohn’s disease by significantly reducing the amount pro-
inflammatory cytokines such as TNFα. In 2002, Borruel et al. obtained ileal samples 
from the surgery of 10 patients with Crohn’s disease and cultured them for 24 hours 
with different dilutions of heat killed L. casei. They found the release of TNFα from 
inflamed mucosa in Crohn’s disease patients was significantly reduced by coculture 
with L. casei. Coculture with L. casei was also found to reduce the number of CD4+ T 
cells as well as TNFα expression among intraepithelial lymphocytes from Crohn’s 
disease mucosa compared to no changes in non-inflamed mucosa. It was therefore 
concluded that the probiotic interacts with immunocompetent cells using the mucosal 
border and then modulates the production of pro-inflammatory cytokines (Borruel et 
al., 2002). This was an important discovery as TNFα has been found to be the 
principal cytokine responsible for the inflammation associated with Crohn’s disease 
(Reimund et al., 2007). Suppressing the action of TNFα using L. casei could 
therefore be used as a possible treatment. In 2005, Herias et al. demonstrated that 
L. casei Shirota (LcS) also has a positive effect on Ulcerative Colitis. A murine model 
of ulcerative colitis was used and the effect of LcS was tested either as a 
prophylactic 10 days before the onset of the disease, simultaneously with ulcerative 
colitis induction, or continued 10 days after the disease was induced. Treatment with 
LcS was found to increase colonic epithelial regeneration in the LcS treated animals 
when observed in the chronic stage.  So although LcS was not able to inhibit the 
effects of ulcerative colitis on the intestinal epithelium entirely, it contributed by 
improving the conditions of the animals, in particular when administered at the time 
of ulcerative colitis induction (Herias, et al., 2005). 
 
Immunomodulatory effects of Lactobacillus casei 
Probiotics have been shown to interact with a wide variety of cells such as 
enterocytes, macrophages, dendritic cells, Th1, Th2, and Tregs in the intestine and 
may modulate the immune response toward a pro- or anti-inflammatory response 
(Gourbeyre et al., 2011). It has been shown in in vitro cell models (enterocytes 
models, such as HT-29, caco-2) that probiotics such as L. casei can influence the 
production of cytokines by intestinal antigen presenting cells (APC) and initiate the 
development of the adaptive response (Gourbeyre et al., 2011).  The results from 
several studies on animals showed that treatment with L. casei increased the 
function of phagocytic cells. In 1983, Saito et al. described how subcutaneously in-
oculating mice with L. casei stimulated the production of specific antibodies against 
Pseudomonas antigens by increasing the level of circulating IgM antibodies. Then in 
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1984, Kato et al. demonstrated using a murine model that intraperitoneally applied L. 
casei activated macrophages by increasing their phagocytic capacity and enzyme 
activity, and in addition, this method induced the activation of natural killer cells (NK) 
which play an important role in preventing tumour development.  Hashimoto et al. 
(1985) established using an in vitro assay that Kupffer cells and immune cells 
associated with spleen, lung and peritoneal macrophages were activated by L. casei 
administration.  The secretion of lysosomal enzymes from macrophages in mice fed 
fermented milk containing L. casei was found to be more effective compared with 
feeding the mice fermented milk containing other probiotic bacteria such as 
Lactobacillus acidophilus (Perdigón et al., 1988). Oral treatment with L. casei led to 
macrophage and lymphocyte stimulation and to the release of enzymes from murine 
macrophages (Perdigón et al., 1986). Subsequent studies by Perdigón et al. (1990, 
1991) showed that treatment with L. casei activated cells in the gut associated 
lymphatic tissue, even at low doses, which led to significantly higher production of 
secretory IgA in the intestinal fluid, providing protection against infections such as 
Salmonella. These results illustrate that L. casei plays an important role in the 
prevention of intestinal infections and administration of L. casei could therefore be 
used as an oral adjuvant for preventing intestinal infections. 
 
L. casei Shirota (LcS) has also been shown to enhance natural killer (NK) cell activity 
(Dong et al., 2010; Takeda et al., 2006). In an in vitro study using human peripheral 
blood mononuclear cells (PBMCs) Dong et al., 2010, found that after incubating the 
cells with LcS at 106 cfu/ml for 24 hours NK cell activity was increased. In another in 
vitro study using PBMCs, heat killed LcS was reported to enhance NK cell activity 
and induce IL-12 production (Takeda et al., 2006). They combined the ability of LcS 
to enhance NK cell activity and induce interleukin (IL)-12 production and found that 
the addition of an anti-IL-12 monoclonal antibody reduced the enhancement of NK 
cell activity triggered by LcS. It was concluded that these results demonstrate how 
LcS can enhance NK cell activity in vivo and in vitro in humans, which may be due to 
IL-12 (Takeda et al., 2006). In another in vitro study, heat-killed LcS was found to 
stimulate IL-10, IL-12, TNFα and IFN-γ production. It also promoted NK cell activity 
and activated CD69 expression on NK cells (Shida et al., 2006). In an in vivo study 
by Takeda and Okumura (2007) volunteers drank fermented milk containing 4 × 1010 
live cells of LcS everyday for three weeks to find that their NK cell activity had 
significantly increased suggesting that daily a intake of LcS provides a positive effect 
on NK cell activity. In contrast to this, in a similar study in 2011, Seifert et al., found 
that LcS did not modulate NK cell activity due to the fact that participants drank a 
probiotic drink identical to the commercially available Yakult product for 4 weeks and 
no significant effect on NK cell numbers or function was observed. This contrast may 
be due to the fact that the probiotic drink used by Takeda and Okumura (2007) 
contained more cells than the probiotic drink used by Seifert et al. (2011). Also, it 
must be taken into account that when administering probiotics via a probiotic drink, 
many of the cells will not reach the intended location of the large intestine as not all 
will survive passage through the stomach and small intestine. This may explain the 
positive results seen in Takeda and Okumura’s (2007) study, as the high number of 
cells in the probiotic drink used would increase the chance of a sufficient number of 
cells reaching the large intestine, where they could exert their effect on the NK cells. 
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Figure 1: Immunomodulatory effects of probiotic such as Lactobacillus casei Shirota. 
Probiotics have been shown to interact with a wide variety of cells such as enterocytes, 
macrophages, dendritic cells, Th1, Th2, and Tregs in the intestine. LcS has been shown to 
increase the cytotoxic activity of NK cells and increase the phagocytic capacity of 
macrophages. LcS also has an effect on T cell activation and cytokine production and can 
modulate the Th1/Th2 balance. Adapted from Shida et al. (2011). 
 
L. casei Shirota (LcS) has been found to have effects on T cell activation and 
cytokine production (Dong et al., 2010; Baken et al., 2006). In an in vitro study by 
Dong et al. (2010) the effects of LcS on immune function using human peripheral 
blood mononuclear cells (PBMC) was investigated and it was found that LcS induced 
CD69 expression on CD4+ and CD8+ lymphocytes and CD25 expression on CD8+ 
lymphocytes. There was also significant evidence of preferential activation of CD8+ T 
cells (Dong et al., 2010). It was also established that LcS has a modulatory effect on 
cytokine production; inducing the production of IL-1β, IL-6, TNF-α, IL-12 and IL-10 in 
the absence of lipopolysaccharide (LPS). However, depletion in monocyte levels 
significantly reduced the effect of LcS on lymphocyte activation and cytokine 
production (Dong et al., 2010).  It has been observed in animal models that 
Lactobacillus casei can also modulate the Th1/Th2 balance toward Th1 activation, 
which has a pro-inflammatory effect (Gourbeyre et al., 2011). This was substantiated 
by Shida et al. (2002) who used a food allergy model to study the Th2 response in 
mice and showed that an intraperitoneal injection of heat-killed L. casei Shirota 
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induced a rise in serum IL-12 levels and a skewing of the cytokine profile from Th2 to 
Th1.  
 
In 2012, Habil et al. established that Lactobacillus casei Shirota (LcS) also 
selectively modulates the cytokine production of different macrophage subsets. M1 
macrophages (pro-inflammatory) and M2 macrophages (anti-inflammatory) were 
treated with heat- killed LcS, activated with the LPS and the cytokines that were 
consequently produced were measured using an ELISA (Habil et al., 2012). They 
found that heat-killed LcS augmented the production of IL-1β and IL-8 in M1’s, but 
suppressed the production of TNFα. In M2’s, TNFα and IL-1β production was 
augmented whereas IL-6 and IL-8 were suppressed (Habil et al., 2012). These 
results lead them to conclude that LcS differentially regulates macrophage subset 
cytokine production. Again, this is an important discovery because being able to 
regulate the production of TNFα using LcS to suppress its production from pro-
inflammatory M1’s could be used as a possible treatment for Inflammatory Bowel 
Diseases such as Crohn’s disease, where TNFα is the main cytokine associated with 
the inflammation. 
 
 
Conclusions 
From these studies it has become clear that the modulation of immune responses by 
LcS can be both anti-inflammatory and pro-inflammatory. LcS has been shown to 
induce the production of inflammatory cytokines such as IL-6, TNFα and IL-12 (Dong 
et al., 2010; Takeda et al., 2006) and to modulate the production of inflammatory 
cytokines by macrophage subsets (Habil et al., 2012). In contrast LcS has also been 
found to suppress the production of TNFα therefore preventing its inflammatory 
effects (Borruel et al., 2002). LcS has also been shown to facilitate the development 
of Th1 cells (Shida et al., 2002) and to enhance NK cell activity (Takeda et al., 2006). 
These immunomodulatory effects could be used to alleviate the symptoms of 
Inflammatory Bowel Diseases such as Crohn’s Disease and Ulcerative Colitis and 
could even lead to future treatments.  
 
However, many of these immunomodulatory mechanisms are still not fully 
understood, and while many positive effects of LcS have been reported, many of 
these studies have included methods using heat-killed LcS. Using heat-killed 
bacteria may produce positive results, but the effect of using live probiotics has 
received less attention so far, and may not deliver such conclusive results.  
  
Further research to investigate the immunomodulatory mechanisms is required and 
studies using live bacteria are needed to confirm the effects of LcS both in vitro and 
in vivo. 
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